Q3 FY2024 · ended Sep 30, 2024 · Revenue $0 · Filed Nov 12, 2025
Palvella Therapeutics, Inc. (PVLA) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $250.6 million in cash and investments and $535,000 in total debt.
Revenue
$0
Net income
$-21.87M
-130.9% vs year-ago quarter
Operating cash flow
$-12.85M
-18.2% vs prior quarter
Free cash flow
$-2.74M
+72.0% vs year-ago quarter
EPS
$-1.52
-76.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
14.41M
+30.3% vs year-ago quarter
Net cash
$250.05M
Q2 FY2026
Operating margin
347.6%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PVLA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Wayne, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1583648
- Former names
- PIERIS PHARMACEUTICALS, INC. (until Dec 12, 2024); Marika Inc. (until Dec 18, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$21.4M | -$14.9M | -$11.3M | -$10.2M | -$9.2M |
| Net income | -$21.9M | -$15.8M | -$12.7M | -$11.3M | -$9.5M |
| Diluted EPS | -$1.52 | -$1.20 | -$1.07 | -$1.03 | -$0.86 |
| Operating cash flow | -$12.8M | -$10.9M | — | — | — |
| Total assets | $253.5M | $263.8M | $59.6M | $66.9M | $73.7M |
| Total liabilities | $36.6M | $31.4M | $31.6M | $28.3M | $26.0M |
| Stockholders' equity | $216.9M | $232.3M | $28.0M | $38.7M | $47.8M |
| Cash and investments | $250.6M | $261.9M | $58.0M | $63.6M | $70.4M |
| Total debt | $535,000 | $584,000 | $633,000 | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 28, 2026 | Oct 28, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Other events
|
Jul 14, 2026 | Jul 14, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 30, 2026 | Jun 29, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 16, 2026 | Jun 10, 2026 |
All 814 Palvella Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.